🎁 Black Friday: up to 50% off of annual plans
Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
50.78
-0.68 (-1.32%)
At close: Nov 20, 2026, 4:00 PM EST
52.48
+1.70 (3.35%)
After-hours: Nov 20, 2026, 7:38 PM EST

Cytokinetics Statistics

Total Valuation

Cytokinetics has a market cap or net worth of $7.07 billion. The enterprise value is $7.37 billion.

Market Cap7.07B
Enterprise Value 7.37B

Important Dates

The last earnings date was Wednesday, November 4, 2026, after market close.

Earnings Date Nov 4, 2026
Ex-Dividend Date n/a

Share Statistics

Cytokinetics has 139.30 million shares outstanding. The number of shares has increased by 8.61% in one year.

Current Share Class 139.30M
Shares Outstanding 139.30M
Shares Change (YoY) +8.61%
Shares Change (QoQ) +5.27%
Owned by Insiders (%) 0.40%
Owned by Institutions (%) 122.12%
Float 138.69M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 62.44
Forward PS 19.57
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 65.06
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.36

Current Ratio 3.36
Quick Ratio 3.29
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -5.17

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -47.70%
Return on Invested Capital (ROIC) -45.76%
Return on Capital Employed (ROCE) -48.14%
Weighted Average Cost of Capital (WACC) 6.98%
Revenue Per Employee $168,337
Profits Per Employee -$1.16M
Employee Count673
Asset Turnover 0.07
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -21.62% in the last 52 weeks. The beta is 0.47, so Cytokinetics's price volatility has been lower than the market average.

Beta (5Y) 0.47
52-Week Price Change -21.62%
50-Day Moving Average 61.89
200-Day Moving Average 69.49
Relative Strength Index (RSI) 29.60
Average Volume (20 Days) 2,097,567

Short Selling Information

The latest short interest is 17.93 million, so 12.87% of the outstanding shares have been sold short.

Short Interest 17.93M
Short Previous Month 18.63M
Short % of Shares Out 12.87%
Short % of Float 12.93%
Short Ratio (days to cover) 10.04

Income Statement

In the last 12 months, Cytokinetics had revenue of $113.29 million and -$777.89 million in losses. Loss per share was -$6.02.

Revenue113.29M
Gross Profit -294.08M
Operating Income -708.24M
Pretax Income -777.89M
Net Income -777.89M
EBITDA -694.73M
EBIT -708.24M
Loss Per Share -$6.02
Full Income Statement

Balance Sheet

The company has $1.13 billion in cash and $1.43 billion in debt, with a net cash position of -$296.84 million or -$2.13 per share.

Cash & Cash Equivalents 1.13B
Total Debt 1.43B
Net Cash -296.84M
Net Cash Per Share -$2.13
Equity (Book Value) -321.17M
Book Value Per Share -2.31
Working Capital 833.73M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$571.97 million and capital expenditures -$16.61 million, giving a free cash flow of -$588.58 million.

Operating Cash Flow -571.97M
Capital Expenditures -16.61M
Depreciation & Amortization 13.52M
Net Borrowing -15.96M
Free Cash Flow -588.58M
FCF Per Share -$4.23
Full Cash Flow Statement

Margins

Gross Margin -259.58%
Operating Margin -625.15%
Pretax Margin -686.63%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Cytokinetics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -8.61%
Shareholder Yield -8.61%
Earnings Yield -11.85%
FCF Yield -8.32%

Analyst Forecast

The average price target for Cytokinetics is $109.42, which is 115.48% higher than the current price. The consensus rating is "Buy".

Price Target $109.42
Price Target Difference 115.48%
Analyst Consensus Buy
Analyst Count 22
Revenue Growth Forecast (3Y) 119.94%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.

Last Split Date Jun 25, 2013
Split Type Reverse
Split Ratio 1:6

Scores

Cytokinetics has an Altman Z-Score of -1.33 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.33
Piotroski F-Score 4